A Prospective Randomized Study of Chop Versus Chop Plus Alpha-2B Interferon in Patients with Intermediate and High Grade Non-Hodgkin's Lymphoma: The International Oncology Study Group NHL1 Study

References

• National Cancer Institute sponsored study of classifications of non- Hodgkin's lymphomas summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002
   PubMed Web of Science ®Google Scholar
• Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non- Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999; 10: 1079
   PubMed Web of Science ®Google Scholar
• Khaled HM, Zekri ZK, Mokhtar N, Ali NM, Darwish T, Elat-Tar I. A randomized EPOCH vs. CHOP front-line therapy for aggressive non- Hodgkin's lymphoma patients: long-term results. Ann Oncol 1999; 10: 1489
   PubMed Web of Science ®Google Scholar
• Ozer H, Wiernik PH, Giles F, Tendler C. Recombinant inter-feron-alpha therapy in patients with follicular lymphoma. Cancer 1998; 82: 1821
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe dEtude des Lympho-mes de l'Adulte. N Engl J Med 1993; 329: 1608
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, Tendler CL, Brice P, Haioun C. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998; 16: 2332
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe dEtude des Lymphomes Folliculaires. Groupe dEtude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110
   PubMed Web of Science ®Google Scholar
• Cole BF, Solal-Celigny P, Gelber RD, Lepage E, Gisselbre-Cht C, Reyes F. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998; 16: 2339
   PubMed Web of Science ®Google Scholar
• Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336
   PubMed Web of Science ®Google Scholar
• Andersen JW, Smalley RV. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up. N Engl J Med 1993; 329: 1821
   PubMed Web of Science ®Google Scholar
• Schiller JH, Hawkins MJ, O'Connell MJ, Sielaff K, Borden EC. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin. J Biol Response Mod 1989; 8: 252
   PubMedGoogle Scholar
• Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148
   PubMed Web of Science ®Google Scholar
• Aviles A, Diaz-Maqueo JC, Garcia EL, Talavera A, Guzman R. Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Invest New Drugs 1992; 10: 351
   PubMed Web of Science ®Google Scholar
• Aviles A, Duque G, Talavera A, Guzman R. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996; 20: 495
   PubMed Web of Science ®Google Scholar
• Aviles A, Talavera A, Diaz NR, Neri N. Interferon as maintenance therapy in refractory malignant lymphoma. J Hematother 1999; 8: 263
   PubMedGoogle Scholar
• Weiss R, Huhn D, Mitrou P, Nerl C, Schurmann D, Scheidegger C. HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk Lymphoma 1998; 29: 103
   PubMed Web of Science ®Google Scholar
• Pautier P, Devidas A, Delmer A, Dombret H, Sutton L, Zini JM. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32: 545
   PubMed Web of Science ®Google Scholar
• Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13: 2916
   PubMed Web of Science ®Google Scholar
• Aviles A, Diaz-Maqueo JC, Talavera A, Garcia EL, Guzman R, Nambo MJ. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Eur J Cancer 1997; 33: 1323
   PubMed Web of Science ®Google Scholar
• Coia L, Krigel R, Hanks G, Comis R, Algazy K, Peters R. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies. Int J Radiat Oncol Biol Phys 1992; 22: 791
   PubMed Web of Science ®Google Scholar
• Richardson DS, Kelsey SM, Johnson SA, Tighe M, Cave-Nagh JD, Newland AC. Early evaluation of liposomal dauno-rubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 1997; 15: 247
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Kantarjian HM, Cortes JE, Thomas DA, Sarris A, O'Brien SM. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, dexamethasone (CVXD) regimen in Richter's syndrome. Blood 1999; 94: 260b
   PubMed Web of Science ®Google Scholar